Browse by Audience
Skip to content
Papers of the Week
Targeting Peroxisome Proliferator-Activated Receptor-α (PPAR- α) to Reduce Paclitaxel-Induced Peripheral Neuropathy.
Abstract
Paclitaxel, a widely used anti-cancer drug, is frequently associated with prolonged and severe peripheral neuropathies (PIPN), associated with neuroinflammation. Currently, PIPN effective treatments are lacking. Peroxisome Proliferator-Activated Receptor-α (PPAR-⍺) can modulate inflammatory responses. Thus, the use of PPAR-⍺ agonists, such as fibrates (fenofibrate and choline-fenofibrate), currently used in dyslipidemia treatment, could represent an interesting therapeutic approach in PIPN.